Bell Investment Advisors’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$628 Hold
43
– – ﹤0.01% 1660
2026
Q1
$320 Hold
43
– – ﹤0.01% 1834
2025
Q4
$506 Hold
43
– – ﹤0.01% 1740
2025
Q3
$332 Hold
43
– – ﹤0.01% 1821
2025
Q2
$315 Sell
43
-98
-70% -$791 ﹤0.01% 1826
2025
Q1
$1.34K Hold
141
– – ﹤0.01% 1454
2024
Q4
$2.32K Hold
141
– – ﹤0.01% 1271
2024
Q3
$2.08K Hold
141
– – ﹤0.01% 1341
2024
Q2
$1.96K Hold
141
– – ﹤0.01% 1364
2024
Q1
$2.22K Hold
141
– – ﹤0.01% 1310
2023
Q4
$2.28K Hold
141
– – ﹤0.01% 1275
2023
Q3
$1.74K Hold
141
– – ﹤0.01% 1353
2023
Q2
$2.27K Sell
141
-50
-26% -$824 ﹤0.01% 1233
2023
Q1
$3.33K Sell
191
-86
-31% -$1.23K ﹤0.01% 987
2022
Q4
$2.56K Sell
277
-7
-2% -$65 ﹤0.01% 1154
2022
Q3
$2K Buy
284
+198
+230% +$1.97K ﹤0.01% 1160
2022
Q2
$1K Buy
+86
New +$821 ﹤0.01% 1510
2021
Q4
$3K Sell
86
-161
-65% -$6.3K ﹤0.01% 1004
2021
Q3
$12K Buy
+247
New +$11.4K ﹤0.01% 408

Other funds holding NEO

Bell Investment Advisors's NEO Position: Q2 2026 in Review

Bell Investment Advisors held its NeoGenomics (NEO) position steady in Q2 2026 at 43 shares worth $628. The position accounts for ﹤0.01% of the portfolio, ranked #1660.

Bell Investment Advisors first reported a position in NEO in Q3 2021 and has held it in 19 quarters since. The position peaked at $12K in Q3 2021. 266 funds tracked by Wall St. Rank hold NEO as of Q2 2026.

  • Bell Investment Advisors held 43 shares of NeoGenomics worth $628 as of Q2 2026.
  • Bell Investment Advisors left its NeoGenomics share count unchanged in Q2 2026.
  • NeoGenomics made up ﹤0.01% of Bell Investment Advisors's portfolio in Q2 2026, its #1660 holding.
  • Bell Investment Advisors first reported a position in NeoGenomics in Q3 2021 and has held it in 19 quarters since.
  • Bell Investment Advisors's NeoGenomics position peaked at $12K in Q3 2021.
  • 266 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2026.

Based on Bell Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.